Sanjay Deshpande, MD, MBBS, DCH, DNB, MNAMS

Dr. Sanjay Deshpande is a Pediatric Infectious Disease Specialist. His extensive education and training include management of a variety of infectious diseases in children with complicated and resistant childhood TB infections, dengue, typhoid, malaria, tropical infections and ICU infections. His expertise lies in management of difficult infections, prolonged fever syndromes, and management of resistant infections and antibiotic stewardship in the ICU setting.

His overseas experience and training include management of children with congenital immunodeficiency, immunosuppression post bone marrow transplant, infections in children with hematological or solid organ malignancy, and complicated COVID-19 infections. These experiences include participating in COVID-19 vaccine trials, pediatric infectious diseases and transplant ID at renown hospitals in India and UK.

He has several publications in national and international journals and is a board review member for PID journals such as Pediatric Infectious Diseases Journal, Pediatric Infectious Disease and Karnataka Pediatric Journal.

[person:personal_statement]

I am deeply committed to providing high-quality, evidence-based care to my patients and their families through a holistic approach that includes active listening and engagement. I believe health care is a partnership, and I strive to treat patients and families as individuals, collaborating with them and personalizing their care to help them achieve their health care goals.

Intereses Clinicos

TB, Tropical ID, Gram negative resistant infections, Newer antibiotics for resistant infections

Educacion

Organizaciones

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Research interests

Outcomes of bacterial, mycobacterial infections in children

King H, Deshpande S, Woodbridge T, et al Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years. Archives of Disease in Childhood, Published Online First: 26 August 2021. doi: 10.1136/archdischild-2021-32265

Sivasankaran M, Munirathnam D, Balasubramanian S, Agrawal S, Deshpande S, Bharadwaj R, Dhanalakshmi K, Kumar V. Diagnostic Spectrum and Clinical Profile of Primary Immunodeficiency Disorders at a Tertiary Care Children Hospital in Southern India. Indian Pediatrics, 2021 Mar 15;58(3):246- 249. PMID: 33713060

Deshpande S, Balaji S. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure? Indian Pediatrics, 2020 Aug 15;57(8):773. doi: 10.1007/s13312-020-1941-4. Epub 2020 Jul 24. PMID: 32710535; PMCID:PMC7444187

Shenoy B, Deshpande S, Dengue fever - Newer insights. Indian Journal of Practical Pediatrics, 2019;21(3): 192-197

Balasubramanian S, Dhanalakshmi K, Sumanth A, Deshpande S, Agrawal S. An Adolescent with Jaundice and Respiratory Distress from the Case Records of Kanchi Kamakoti CHILDS Trust Hospital. Pediatric Infectious Disease, 2019;1(1):39-41

Balasubramanian S, Deshpande S. Vaccination In Special Situations. Indian Journal of Practical Paediatrics, 2021; 23(1):10, 19-28

Bijker EM, Deshpande S, Salgame P, Song R. Malaria, and tuberculosis co-infection – A review. Accepted for publication by Oxford Open Immunology